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CD8 but not CD4T cells require cognate interactions with target tissues to
mediate GVHD across only minor H antigens, whereas both CD4 and CD8
T cells require direct leukemic contact to mediate GVL
Catherine Matte-Martone,1 Jinli Liu,2 Dhanpat Jain,3 Jennifer McNiff,4 and Warren D. Shlomchik1,5
1Section of Medical Oncology, Cancer Center, Yale University School of Medicine, New Haven, CT; 2Department of Pathology, Hartford Hospital, Hartford, CT;
and Departments of 3Pathology, 4Dermatology, and 5Immunobiology, Yale University School of Medicine, New Haven, CT
Whether T-cell antigen receptors (TCR)
on donor T cells require direct interac-
tions with major histocompatibility
complex class I or class II (MHCI/MHCII)
moleculesontargetcellstomediategraft-
versus-host disease (GVHD) and graft-
versus-leukemia (GVL) is a fundamental
questioninallogeneicstem-celltransplan-
tation (alloSCT). In MHC-mismatched
mouse models, these contacts were not
required for GVHD. However, this conclu-
sion may not apply to MHC-matched,
multipleminorhistocompatibilityantigen-
mismatched alloSCT, the most common
type performed clinically. To address this,
we used wild-type (wt)3MHCI/ or
wt3MHCII/ bone marrow chimeras as
recipients in GVHD experiments. For
GVL experiments, we used MHCI/ or
MHCII/ chronic-phase CML cells cre-
ated by expressing the BCR-ABL cDNAin
bone marrow from MHCI/ or MHCII/
mice. TCR/MHCI contact was obligatory
for both CD8-mediated GVHD and GVL.
In contrast, CD4 cells induced GVHD in
wt3MHCII/chimeras,whereasMHCII/
mCP-CML was GVL-resistant. Donor CD4
cells inﬁltrated affected skin and bowel in
wt3MHCII/ recipients, indicating that
they mediated GVHD by acting locally.
Thus, CD4 cells use distinct effector
mechanisms in GVHD and GVL: direct
cytolytic action is required for GVL but
not for GVHD. If these noncytolytic path-
ways can be inhibited, then GVHD might
be ameliorated while preserving GVL.
(Blood. 2008;111:3884-3892)
© 2008 by TheAmerican Society of Hematology
Introduction
Allogeneic hematopoietic stem-cell transplantation (alloSCT) is a
potentially curative therapy for hematologic malignancies, inherited
disorders of blood cells including sickle cell anemia, and acquired
nonmalignant diseases such as aplastic anemia. Mature donor T cells in
allografts play 2 important functions. First, they are pivotal for reconsti-
tuting T-cell immunity, particularly in adult patients who have incom-
pleteanddelayedgenerationofprogenitor-derivedTcellsresultingfrom
age-dependent thymic involution and damage to the thymus by condi-
tioning regimens.1-3 Second, they mediate a potent antineoplastic effect
called graft-versus-leukemia (GVL).4 Unfortunately, donor T cells can
also broadly attack the recipient in a process called graft-versus-host
disease (GVHD). Because of GVHD, all patients receive some form of
prophylactic immunosuppression. Nonetheless, GVHD and the infec-
tious complications of immunosuppression remain major sources of
morbidityandmortality,whichpreventthemorewidespreadapplication
of alloSCT. A detailed mechanistic understanding of how T cells
mediate GVHD and GVLwill be essential for developing strategies for
minimizingGVHDandformaximizingGVLandimmunereconstitution.
A fundamental question regarding how T cells mediate GVHD
is whether cognate interactions between T-cell antigen receptors
and major histocompatibility complex (MHC) on nonhematopoi-
etic target tissues (eg, skin, liver, and bowel) are required. Prior
work by Teshima et al has suggested that CD4-mediated GVHD,
and to a lesser extent CD8-mediated GVHD, do not require such
direct interactions.5 In these experiments, GVHD and death were at
least in part cytokine-mediated.
However, these conclusions were drawn from rapidly lethal
GVHD models in which the donor and recipient were MHC-
mismatched. This is in contrast to the majority of human alloSCTs
in which donor and recipient MHC are matched or genotypically
identical. MHC-mismatched and MHC-matched alloSCTs differ in
the identities of the antigens targeted by donor alloreactive T cells.
In MHC-mismatched GVHD, T-cell receptors (TCRs) on donor
T cells at least in part directly recognize intact recipient MHC.6-8 In
contrast, alloreactive T cells in MHC-matched alloSCT recognize
minor histocompatibility antigens (miHAs), which are the peptide
products of polymorphic genes that distinguish recipients from
donors, conventionally presented by MHC molecules.4,9 A conse-
quence of targeting MHC vs miHAs is that the precursor frequency
of T cells that recognize MHC is as high as 1% to 10% of T cells,
much greater than the estimated 1 in 104 t o1i n1 0 6 T cells that
recognize peptide antigens, such as miHAs. Consequently, when
T cells are transferred as part of a MHC-disparate alloSCT, a large
number synchronously activate and expand, which results in
elaborationofcytokinesinsufﬁcientquantitiestoresultindeath.5,10
In such models, death can occur with few T cells inﬁltrating target
tissues, consistent with the idea that cytokines act at a distance in an
endocrine fashion. However, in MHC-matched, multiple miHA-
mismatched alloSCTs, because fewer alloreactive T cells are
transferred, mice (and humans) typically survive this early burst of
cytokines and GVHD is instead primarily manifest by T-cell
inﬁltration of target tissues. Thus, it is possible that in this
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cause GVHD.
Another implication of the studies by Teshima et al5 was that
parenchymal alloantigen itself is not even required for GVHD
because in their experiments both donors and recipients were on the
B6 background and differed only at loci within the MHC gene
complex. The requirement for parenchymal miHA expression has
been addressed in MHC-matched murine allogeneic bone marrow
transplant (alloBMT) models wherein host3donor bone marrow
(BM) chimeras, in which only hematopoietic cells in the recipient
are allogeneic, were used as recipients in a second transplant with
GVHD-inducing CD4 or CD8 cells.11,12 These chimeras were
resistant to both CD4- and CD8-mediated GVHD, clearly demon-
strating that allogeneic recipient hematopoietic cells alone are not
sufﬁcient for miHA-directed GVHD and that parenchymal tissues
must express alloantigen. However, these experiments did not
address whether donor T cells must make cognate interactions with
recipient parenchyma; rather, they demonstrate that miHA-
expressing parenchyma is required.
To determine whether donorTcells require cognate interactions
with recipient parenchyma to induce GVHD in MHC-matched
alloBMT, we used wild-type (wt)B 6 3B6 beta-2-microblobulin
gene-deﬁcient (2M/ and therefore MHCI) and wt B63B6 IAb
beta chain gene-deﬁcient (IAb/ and therefore MHCII)B M
chimeras as recipients in a second transplant in which GVHD was
induced by puriﬁed donor CD8 or CD4 cells. We also studied
whether cognate interactions are required for CD4- and CD8-
mediated GVLin the same strain pairings.
Methods
Mice
Mice were between 7 and 10 weeks of age. C3H.SW (H-2b) mice were
originally purchased from The Jackson Laboratories (Bar Harbor, ME) and
bred at Yale University. 129S1/SvImJ/Cr (129), C57BL6 (B6), and B6
CD45.1 congenic mice were obtained from the National Cancer Institute
(Frederick, MD). IAb beta chain deﬁcient (IAb/) mice were obtained
from Taconic Farms (Germantown, NY). 2M/ mice were obtained from
Jackson ImmunoResearch Laboratories.
Cell puriﬁcation
CD8 cells were puriﬁed from lymph nodes (LN) via negative selection as
previously described13 using biotin-conjugated antibodies against CD4
(clone GK1.5; laboratory-prepared), B220 (clone 6B2; laboratory-
prepared), CD11c (clone HL3; BD PharMingen, San Diego, CA), and
CD11b (clone M1/70; BD PharMingen), followed by streptavidin-
conjugated magnetic beads (Miltenyi Biotec, Auburn, CA) and separation
on an autoMACS (Miltenyi Biotec). CD8 cells were more than 90% pure
with CD4 T cell contamination of less than 0.2% (not shown). CD4 cells
were similarly puriﬁed by negative selection, except that GK1.5 was
omitted and biotin-conjugated anti-CD8 (TIB105; laboratory-prepared)
was added to the antibody depletion cocktail. BM T cells were depleted
withanti-Thy1.2magneticmicrobeads(MiltenyiBiotec)andtheautoMACS.
GVHD transplant protocol
All transplants were performed according to protocols approved by theYale
University InstitutionalAnimal Care and Use Committee.
Bone marrow chimeras
To create wt32m/, wt3wt,o rwt3IAb/ chimeras, recipient
mice received 2 500-cGy fractions (separated by 3 hours) from a
cesium irradiator and were reconstituted with 107 T cell–depleted (TCD)
B6 CD45.1 BM. Two to 3 months later, chimeras were reirradiated
(2  450 cGy) and reconstituted with TCD donor BM (C3H.SW or 129)
with puriﬁed donor CD4 or CD8 T cells. Mice were weighed and scored
for GVHD 2 to 3 times per week. Weights from mice that died or
were killed because of GVHD morbidity were included in averages for
subsequent time points at the last value recorded.
Analysis of dendritic cell engraftment
Spleens and LNs were digested with collagenase as described.13,14 To
distinguish residual recipient (CD45.2/MHCI or MHCII), and donor-
derived B6 (CD45.1MHCIMHCII) DCs in initial BM chimeras,
preparations were stained with antibodies against CD45.1 or CD45.2
(FITC; clones A20 and 104; BD PharMingen), CD11c (APC; clone HL3;
BD PharMingen), a cocktail of biotin-conjugated antibodies against Gr-1
(clone RB6-8C5; BD PharMingen), CD19 (BD PharMingen; clone 1D3),
Ly76 (TER119; BD PharMingen), and Thy1.2 (clone 30H12; laboratory-
prepared), and MHCI (PE; clone 2B-11-5S; BD PharMingen) or MHCII
(PE; clone MS/114.15.2, BD PharMingen). Cells were washed and stained
with streptavidin-PerCP (BD PharMingen). DCs were identiﬁed as being
CD11c/lineagelow/propidium iodide.
Histologic analysis
Tissues were ﬁxed in 10% phosphate-buffered formalin, parafﬁn-embedded,
sectioned, and stained with hematoxylin and eosin (H&E). Slides were read by
pathologists expert in skin (J.M.) and gastrointestinal disease (D.J.) without
knowledge as to experimental group as we have described.15 Images of bowel
and liver were obtained with an Olympus BX40 microscope (OlympusAmerica,
Lakewood, CO) using a 10 eyepiece and an 20 objective, with a QImaging
QColor5 camera (Olympus) and QCapture software (Olympus). Images were
processed with Adobe Photoshop 7.0 software (Adobe Systems, San Jose, CA).
Images of skin were obtained with an Olympus BX40 microscope (Olympus)
using a 10 eyepiece, 20 objective, a Scanalytics SPOT RT Slider camera
(model 2.3.1; Diagnostic Instruments, Sterling Heights, MI), SPOT soft-
ware version 4.06 (Diagnostics Instruments) followed by processing with
Adobe Photoshop 7.0.
Immunoﬂuorescent staining
Tissues were ﬁxed in 0.7% formaldehyde overnight followed by dehydra-
tion in 30% sucrose and freezing in Tissue-TeK OCT compound (Sakura
Finetek, Torrance, CA); 7-m sections were incubated overnight at 4°C
withDAPIandantibodiesagainstCD4(Alexa647;cloneGK1.5;laboratory-
prepared) and MHCII (biotin, clone M5/114.15.2; BioLegend, San Diego,
CA), followed by incubation with streptavidin-Alexa568 (Invitrogen,
Carlsbad, CA). Sections were imaged with an Olympus BX40 microscope
using a 10 eyepiece, 40 objective, a Scanalytics SPOT RT Slider
camera (model 2.3.1, Diagnostic Instruments) using SPOTsoftware version
4.06 (Diagnostics Instruments). Pictures were reconstituted with Adobe
Photoshop 7. CD4 was rendered in green, MHCII in red, and DAPI in blue.
Retrovirus production
MSCV2.2 expressing the human bcr-abl p210 cDNA and a nonsignaling
truncated form of the human low afﬁnity nerve growth factor receptor
(NGFR), driven by an internal ribosome entry site (Mp210/NGFR), was a
gift of Warren Pear. Retroviral supernatants were generated by transfection
of Plat-E retrovirus packing cell line16 as described.17-19
Progenitor infections
p210-infected progenitors were generated as previously described.13,17,19
Brieﬂy, B6 mice were injected on day 6 with 5 mg 5-ﬂuorouracil
(Pharmacia & Upjohn, Kalamazoo, MI). On day 2, BM cells were
harvested and cultured in prestimulation media (Dulbecco modiﬁed Eagle
medium, 15% fetal bovine serum, interleukin-3 (6 ng/mL), interleukin-6
(10 ng/mL), and stem-cell factor (10 ng/mL; all cytokines from PeproTech;
Rocky Hill, NJ). On days 1 and 0, cells underwent “spin infection” with
the Mp210/NGFR retrovirus.19
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On day 0, B6 hosts received 2 450-cGy fractions and were reconstituted
with 5  106TCD C3H.SWor 129 BM with 7  105 wt B6, B6 2M/,o r
B6 IAb/ BM cells that underwent spin infection, with or without
1.2  106 puriﬁed wt C3H.SW CD8 T cells or 4  106 129 or C3H.SW
CD4 T cells. For CD8 GVL experiments, all recipients (including those
that received wt mCP-CML) were injected with 200 g intraperitoneally of
anti-NK1.1 (PK-136; laboratory-prepared) on days 2, 1, and 7 to
prevent NK cell–mediated rejection of 2M/ mCP-CML. Peripheral
blood was analyzed for the presence of NGFR cells by ﬂow cytometry.
Cause of death was determined by the presence of NGFR cells at the bleed
before death and by spleen weight at necropsy.
Results
CD8-mediated GVHD
For these experiments, we used the MHC-matched C3H.SW
(H-2b)3B6 (H-2b) strain pairing in which puriﬁed C3H.SW CD8
T cells induce GVHD.13,14 To determine whether donor T cell
TCR:target MHC I contacts are required for CD8-mediated GVHD
across only miHAs, we wanted a recipient mouse with MHCI
parenchyma but with MHCI antigen presenting cells (APCs),
which are required for GVHD in this model.14 We created such a
mouse by making B6 CD45.13B6 CD45.2 2M/ BM chimeras
(wt32M/; Figure 1). We also created control B6 CD45.13B6
CD45.2 chimeras (wt3wt; Figure 1). Cohorts of mice were killed
between days 87 and 90 after alloBMT, and engraftment was
analyzed in spleen and LN. Overall, splenocytes were 90% to 95%
donor-derived in both sets of chimeras. In particular, dendritic cells
(DCs) were well engrafted, with more than 95% of LN and splenic
DCs being of donor origin (Figure 2). This conﬁrmed that the
wt32M/ chimeras had sufﬁcient wt APCs such that any
differences in GVHD between the 2 sets of chimeras would not be
attributable toAPC composition.
We then used these chimeras as recipients in a second GVHD-
inducing alloBMT with C3H.SW donors (Figure 1). In 2 indepen-
dent experiments, wt32M/ chimeras were nearly completely
resistant to CD8-mediated GVHD as measured by weight loss
(Figure 3) and histologic analysis of GVHD target organs (Figure
4). We found no evidence of GVHD pathology in skin, liver, small
intestine, and colon in wt32M/ recipients of donor CD8 cells.
In contrast, wt3wt recipients of donor CD8 cells developed
signiﬁcant GVHD in each organ (Figure 4). The only suggestion of
GVHD in wt32M/ CD8 recipients was low-penetrance GVHD
of the ear, although, compared with control wt32M/ mice that
did not receive CD8 cells, scores did not reach statistical signiﬁ-
cance (P  .184). Thus, with the possible exception of the ear,
donor CD8 T cells absolutely required cognate interactions with
MHCI on parenchyma to cause GVHD.
To address the possibility that wt32M/ mice did not
develop GVHD because of poor donor CD8 cell engraftment,
we enumerated splenic CD8 cells at the time of death (day 35).
Hematopoietic cells in wt (CD45.1)32M/ (CD45.2) chime-
ras were mostly CD45.1, which allowed us to distinguish
CD45.1 C3H.SW-derived and residual CD45.1 recipient CD8
cells. However, there were no Thy1.1 or CD45.1 congenic
C3H.SW mice available that would have permitted us to use
C3H.SW BM and CD8 cells that differed at one of these to allow
us to distinguish infused C3H.SW CD8 cells from those derived
from donor BM. However, by comparing donor CD8 cell
numbers in recipients of only donor BM to recipients of BM and
CD8 cells, an estimation of what is derived from infused mature
CD8 cells can be made. Moreover, because thymic epithelial
cells in wt32M/ recipients do not express MHCI, we
Figure 1. Experimental design. (A)To create mice with MHCI or MHCII parenchyma but with MHC hematopoietic cells (includingAPCs), B6 2M/ or IAb/ mice (both
CD45.2) were irradiated and reconstituted with TCD wt B6 CD45.1 BM. (B) After 3 months to allow for engraftment of the wt B6 hematopoietic system, these chimeras were
used as recipients in a second, GVHD-inducing alloBMT.
Figure 2. Dendritic cells in B6 CD45.13B6 2M/ or B6 IAb/ are mostly donor in origin. Spleens and LNs were collagenase-treated, and cells were stained with a
cocktail of lineage antibodies, anti-CD11c and anti-CD45.1 or CD45.2 (“Analysis of dendritic cell engraftment”). Shown is CD45.1 (O) and CD45.2 () staining of lineagelow
CD11c cells from representative mice (at least 3 mice were analyzed from each group in each experimental repetition).
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derived CD8 cells. As expected, we detected few if any
donor-derived CD8 cells in wt32M/ recipients of only
C3H.SW BM. In contrast, in a representative GVHD experi-
ment, wt32M/ chimeric recipients of C3H.SW BM and
CD8 T cells had a mean of 1.6  106 (SD  3.3  105;
n  15) splenic C3H.SW CD8 cells, similar to that found in
wt3wt recipients of CD8 cells (1.4  106;S D  3.1  105;
n  15). These cells were mostly CD44CD62L, consistent
with having been previously activated or having underwent
lymphopenia-induced proliferation, making it highly probable
that these were derived from infused mature CD8 cells. Thus,
the failure of wt32M/ chimeras to develop GVHD was not
the result of poor engraftment of donor CD8 T cells.
CD4-mediated GVHD
For these experiments, we used the MHC-matched, miHA-
disparate 129 (H-2b)3B6 (H-2b) strain pairing. To determine
whether donor T cell TCR:target MHCII interactions are required
for CD4-mediated GVHD, we generated BM chimeras to create
recipient mice in which the parenchyma was MHCII but the
hematopoietic cells, including APCs, were MHCII. B6 CD45.2
IAb/ and therefore MHCII-deﬁcient mice were irradiated and
reconstituted with B6 CD45.1 BM (wt3IAb/). As controls we
also created B6 CD45.13B6 CD45.2 (wt3wt) chimeras. Cohorts
of these chimeric mice were killed between days 90 and 92 after
BMT to assess donor B6 CD45.1 hematopoietic engraftment.
Overall, splenocytes were 90% to 92% donor-derived in
wt3IAb/ and wt3wt chimeras. In particular, DCs were well
engrafted in both sets of chimeras, with  95% of LN and splenic
DCs being of donor origin (Figure 2). This conﬁrmed that the
wt3IAb/ chimeras had sufﬁcient wt APCs such that any
differences in GVHD seen between the 2 sets of chimeras would
not be attributable toAPC composition.
We then used these chimeras as recipients in a second GVHD-
inducing alloBMT. In contrast to what we observed with CD8-
mediated GVHD, donor CD4 T cells induced clinical (Figure 5)
and histologic GVHD (Figure 6) in wt3IAb/ chimeras that was
equivalent to, if not more severe than in, wt3wt chimeras.
Compared with wt3IAb/ recipients of only donor BM,
wt3IAb/ CD4 recipients had histologic GVHD of the liver,
skin, small intestine, and colon. GVHD pathology in wt3IAb/
CD4 recipients was equivalent to that in wt3wt CD4 recipients in
the liver and colon and was more severe in the small intestine and
skin (Figure 6). Thus, cognate interactions between donor T cells
and MHCII on recipient parenchymal tissues were not required for
CD4-mediated GVHD across only miHAdifferences.
Grossly similar cellular inﬁltrates were present in hematoxy-
lin and eosin-stained sections from GVHD target tissues in both
wt3wt and wt3IAb/ CD4 recipients (Figure 6), which we
presume were pathogenic because they were absent in recipients
of only donor BM. To conﬁrm that CD4 cells were a component
of the inﬁltrate, we performed immunoﬂuorescent microscopy
on skin and small intestine. We observed clear CD4 inﬁltrates
in skin and bowel of wt3IAb/ and wt3wt recipients of CD4
cells, not present in BM alone controls (Figure 6C) or in
unmanipulated wt mice (not shown). These CD4 cells were
frequently adjacent to MHCII cells, suggesting that interac-
tions between donor CD4 cells and MHCII cells, such as
macrophages and tissue DCs, contribute to GVHD pathogenesis
(see “Discussion”).
Role of cognate TCR/MHC interactions in GVL
Having established the roles of TCR/MHC interactions in GVHD,
we investigated these requirements for T cells mediating GVL. To
do so, we used a murine model of chronic-phase chronic myelog-
enous leukemia (mCP-CML) wherein mCP-CMLis induced by the
retroviral introduction of the human bcr-abl fusion cDNA into
mouse hematopoietic progenitors. mCP-CML phenotypically re-
sembles human CP-CML in that recipients of p210-infected BM
cells develop a high white blood cell count and splenomegaly, with
hematopoiesis dominated by maturing myeloid cells.13,17,19 An
advantage of this model is that we can induce mCP-CML in BM
from any strain, including gene-deﬁcient mice. The retroviral
construct also expresses a nonsignaling truncated form of the
Figure 3. Wt32M/ chimeric recipients are resistant to CD8-mediated GVHD. Shown is percentage weight change versus day after alloBMT from 2 independent
experiments. Numbers of mice per group in each repetition are listed (separated by commas; *P  .05, CD8 recipients vs recipients of only TCD C3H.SW BM). Weight change
was not signiﬁcantly different at any time point comparing wt32M/ recipients of only C3H.SW TCD BM and TCD BM plus CD8 cells.
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To determine whether cognate T cell/leukemia interactions are
required for GVL, we tested whether CD8 or CD4 T cells could
mediate GVL against mCP-CML created from B6 2M/ or B6
IAb/ BM, respectively. To directly compare the roles of cognate
interactions in GVL and GVHD, we used the same strain pairings
as in the prior GVHD experiments, except in this case recipients
were wt B6 mice and not BM chimeras. For CD8-mediated GVL,
irradiated B6 mice were reconstituted with TCD C3H.SW BM,
either wt B6 or 2M/ B6 mCP-CML, with or without donor
C3H.SW CD8 cells. To prevent NK cell-mediated rejection of
2M/ mCP-CML, all mice (including recipients of wt mCP-
CML) were treated anti-NK1.1 on days 2, 1, and 7 to deplete
NK cells.13 As expected, CD8 cells mediated GVL against wt B6
mCP-CML (Figure 7A). However, 2M/ mCP-CML was com-
pletely resistant to CD8-mediated GVL. Thus, donor CD8 cells
required cognate interactions with MHCI to mediate GVL.
Figure 4. Only wt3wt and not wt32M/ chimeric recipients of C3H.SW CD8 cells develop histologic GVHD. (A) Representative histology (original magniﬁcation
200). (B) Combined histology scores from 2 independent experiments. Each symbol is the score from an individual mouse; horizontal lines represent mean scores. P values
are shown below the group labels.
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with TCD 129 BM, either wt B6 or B6 IAb/ mCP-CML, with or
without puriﬁed 129 CD4 cells. Donor CD4 cells mediated GVL
against wt mCP-CML but not against IAb/ mCP-CML (Figure
7B). Thus, in contrast to CD4-mediated GVHD and consistent with
our prior experiments with IAb/ mCP-CML in a different strain
pairing,19 CD4-mediated GVL required cognate interactions with
MHCII mCP-CMLcells.
IAb/ mCP-CML could have been GVL-resistant because
leukemia cells were important APCs. If so, GVL may have been
reduced because of inadequate generation of alloreactive effector
CD4 cells rather than because of an inability of effectors to kill
MHCIItargets.Toaddressthispossibility,wedeterminedwhether
GVL would be intact against IAb/ mCP-CML if mice also
received wt MHCII mCP-CML (Figure 7C). We reasoned that, if
priming by MHCII mCP-CML cells is important, then the
presence of wt mCP-CML would “rescue” GVL against IAb/
mCP-CML. For these experiments, we used the C3H.SW3B6
strain pairing. B6 mice were irradiated and reconstituted with
C3H.SW TCD BM, B6 wt mCP-CML, or B6 IAb/ mCP-CML,
or a 1:1 mix of wt and IAb/ mCP-CML with or without 4  106
puriﬁed C3H.SW CD4 cells.All mice received 7.5  105 BM cells
that underwent spin infection (recipients of a mix of wt and IAb/
mCP-CML received 3.75  105 cells of each). As expected, donor
CD4 cells mediated GVL against wt mCP-CML. In contrast,
recipients of IAb/ mCP-CMLand CD4Tcells, with or without
additional wt mCP-CML, died from mCP-CML with similar
kinetics (P  .96). Survival in these groups was similar to that in
recipients of IAb/ mCP-CML and no donor CD4 cells (P  .77
comparing wt  IAb/ mCP-CML and CD4 cells to IAb/
mCP-CML without CD4 cells). Thus, even in the presence of wt
mCP-CML, IAb/ mCP-CML was resistant to CD4-mediated
GVL. Therefore, the requirement for cognate interactions between
TCRs on donor CD4 cells and MHCII on mCP-CML is in the
effector and not the priming phase of GVL.
Discussion
In the present work, we deﬁne the requirements for cognate T cell
contact with parenchymal tissues and leukemia cells in clinically
relevant, MHC-matched, multiple miHA-mismatched models of
GVHD and GVL. CD8-mediated GVHD (aside from low-
penetrance GVHD of ears, which did not make statistical signiﬁ-
cance) absolutely required direct interactions between TCRs on
donor CD8 cells and MHCI on target tissues. We observed neither
clinical GVHD nor histologic GVHD in skin, small intestine,
colon, and liver of wt32M/ recipients of CD8 T cells. Thus,
in contrast to the situation in MHC-disparate GVHD,5 T cell or
T cell–induced cytokine production and cytolytic-targeting of only
recipient hematopoietic cells was insufﬁcient for GVHD in a
MHC-matched, multiple miHA-mismatched model.
Because alloreactive CD8 T-cell generation was intact in
wt32M/ recipients, given that recipient APCs were MHCI,
initial recruitment of alloreactive activated T cells into potential
GVHD target tissues should not have been impaired.21,22 That we
saw no evidence of inﬁltrating lymphocytes in these chimeras
highlights the importance of tissue damage in the accumulation of
donor CD8 T cells. Such accumulation could be the result of
increased T-cell recruitment from blood, local retention and
survival of T cells after entering tissues, and perhaps by local T-cell
expansion driven by host antigen-bearing tissue APCs. We previ-
ously demonstrated that maximal GVHD in this system requires
functional donor APCs which probably promote GVHD by cross-
presenting recipient antigen to donor CD8 cells.13 Although this
clearly could be occurring in secondary lymphoid tissues, it could
also be taking place in GVHD target organs, and parenchymal cells
killed by alloreactive T cells could be a source of cross-presented
antigen. The topical administration of a Toll-like receptor-7 agonist
was recently shown to promote localized GVHD, presumably by
enhancing recruitment of alloreactive T cells.23 Our data extend
that work by showing that initial T-cell recruitment is not enough
and that a critical mass of tissue damage is necessary to establish a
sustained GVHD lesion.
We do not know why wt32M/ CD8 recipients may have
developed low-penetrance GVHD of the ear. One possibility would
be that parenchymal cells acquire sufﬁcient soluble 2M, or even
intact MHCI contained in exosomes derived from wt hematopoietic
cells, to permit direct cytolytic damage.24-27 Alternatively, local
releaseofinﬂammatorymediators,includingcytokinesandperforin/
granzymes, by CD8 T cells reacting with host antigen-bearing
MHCI donor APCs may injure bystander MHCI tissues. Either
effect could be potentiated by underlying damage from irradiation,
which disproportionately affects the ears. Nonetheless, the key
conclusion is that overall cognate interactions between TCRs and
MHCI are pivotal for histologic GVHD.
Cytolytic mechanisms in CD8-dependent, miHA-disparate,
MHC-matched GVHD have been studied using T cells deﬁcient in
perforin, FasL, or both.28 Perforin/FasL double-deﬁcient T cells
induced GVHD across only miHA differences, albeit with delayed
Figure 5. Both wtgwt and wt3IAb/ donor CD4 recipients developed GVHD-induced weight loss. Shown is percentage weight change versus day after BMT from
3 independent experiments. Numbers of mice per group in each repetition are listed, separated by commas (*P  .05, CD4 recipients [either wt3wt or wt3IAb/]v st h e
appropriate recipients of only TCD 129 BM).
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labels. (C) Immunoﬂuorescent staining of small intestine and skin from both wt3wt and wt3IAb/ recipients of 129 CD4 T cells. Blue indicates DAPI-stained nuclei; green,
CD4 cells; red, MHCII cells. Note inﬁltrating CD4 cells in both bowel and skin of CD4 recipients, frequently adjacent to MHCII cells.
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the extent that the major cytolytic mechanisms were impaired, the
GVHD observed could have been the result of activities that do not
rely on direct TCR contact with target tissues. Our result that
CD8-dependent GVHD requires cognate interactions between
donor T cells and parenchyma clariﬁes that result and suggests that
GVHD induced by FasL/perforin double-deﬁcient CD8 cells was
likely the result of direct killing of MHCI parenchymal cells by
other cytolytic effectors, such as tumor necrosis factor-	 and tumor
necrosis factor-	–related apoptosis-inducing ligand.
In contrast to CD8-mediated GVHD, TCRs on donor CD4 cells
did not require cognate interactions with MHCII on parenchymal
tissues to mediate GVHD. It was reasonable to propose that
CD4-mediated GVHD in MHC-matched transplants might depend
on parenchymal interactions between TCR and MHCII as MHCII
is expressed by inﬂamed bowel epithelial cells and keratinocytes,
speciﬁcally in mice with GVHD.13,30-32 Nonetheless, cognate
interactions were not required, although our studies do not exclude
that they additionally contribute to GVHD pathology. If anything,
GVHD was more severe in wt3IAb/ mice. This increased
severity could have been the result of the absence of recipient
CD4CD25FOXP3 regulatory T cells which would not have
been positively selected as thymic epithelial cells are MHCII in
wt3IAb/ chimeras.33
We observed similar polymorphonuclear inﬁltrates in GVHD
target tissues in either wt3wt or wt3IAb/ CD4 recipients, not
present in mice that received onlyTCD donor BM. Immunoﬂuores-
cence staining conﬁrmed the presence of inﬁltrating CD4 T cells
in both wt3wt and wt3IAb/ CD4 recipients, consistent with
their having a pathogenic role. We see several nonexclusive
mechanisms whereby inﬁltrating CD4 cells could cause tissue
damage without directly contacting nonhematopoietic tissues.
After activation in secondary lymphoid organs, donor CD4 cells
could migrate into target tissues and elaborate inﬂammatory
mediators without any additional activation. Alternatively or in
addition, inﬁltrating alloreactive CD4 cells could be further
activated in target organs by miHA-bearing MHCII cells, such as
tissue DCs and macrophages, thereby amplifying the GVHD
response locally. Our demonstration of CD4 cells adjacent to
MHCII cells in GVHD target tissues supports this notion. Donor
CD4 cells could reciprocally activate tissue MHCII cells, and this
might need to occur before they activate inﬁltrating CD4 cells.
Consistent with this idea, we previously reported reduced GVHD
when donor BM was CD40-deﬁcient.34 CD4 cells could also arm
miHA-expressing macrophages to induce tissue damage. This is a
compelling mechanism because CD8 T cells, which could not
mediate GVHD indirectly, are not well equipped for this function.
A more deﬁnitive investigation on a potential role for tissue
macrophages will require the use of donors that have constitutive or
preferably inducible defects in macrophage effector function.35,36
Further clariﬁcation of this mechanism could identify novel
therapeutic targets for treating or preventing GVHD that could
spare the GVLeffect.
By creating MHCI and MHCII leukemias, we investigated
the requirement for TCR/leukemia target interactions in GVL.
CD8-mediated GVL mirrored CD8-mediated GVHD in that it
required cognate interactions between donor CD8 cells and
leukemic targets. Although this was an anticipated result, a
requirement for MHCI expression by target leukemias for
CD8-mediated GVL had never been deﬁnitively tested. Prior
work in an MHCI-mismatched, miHA-matched model sug-
gested that some GVL can occur when donor T cells are
syngeneic to and therefore MHCI-matched with the targeted
leukemia,37 which implies indirect killing, not observed in our
experiments. In contrast, only CD4-mediated GVL, and not
CD4-mediated GVHD, required contact with MHCII on targets.
mCP-CML cells are uniformly MHCI; however, because p210
expression does not block myeloid differentiation in human or
Figure 7. 2M/ and IAb/ mCP-CML are resistant to CD8- and CD4-mediated GVL. (A) B6 mice were irradiated and reconstituted with TCD C3H.SW BM, wt B6 or
2M/ mCP-CML, with or without C3H.SW donor CD8 T cells. (B) B6 mice were irradiated and reconstituted with TCD 129 BM, wt B6 or IAb/ mCP-CML, with or
without puriﬁed 129 CD4 T cells. (C) To determine whether the GVLresistance of IAb/ mCP-CMLis in the effector phase, irradiated B6 mice were reconstituted with
TCD C3H.SW BM, wt mCP-CML, or IAb/ mCP-CML or a mix of both wt and IAb/ mCP-CML, with or without puriﬁed C3H.SW CD4 T cells. Note that the only
survivors were recipients of wt mCP-CML cells and donor C3H.SW CD4 cells, indicating that IAb/ mCP-CML is GVL-resistant because of a defect in the effector
phase. (D) Experimental design for panel C.
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expression (not shown). However, we infer from these data that
a key cell, perhaps a leukemia stem cell, is MHCII and this is
currently being investigated. The requirement for cognate
interactions for GVLis not restricted to mCP-CML, but we have
also found it to be required for GVL against a murine model of
blast crisis CML.38 Thus, alloreactive CD4 cells mediate GVL
and GVHD using distinct mechanisms. This was an unexpected
result, which has important clinical implications. If the speciﬁc
pathways engaged by CD4 cells in GVHD and not in GVL are
fully elucidated, they could be targeted to mitigate GVHD,
possibly without compromising GVL.
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